Recently, at the “New Advances in Hypertension Management” symposium during the 2026 American College of Cardiology Scientific Session (ACC.26), Professor Li Haiyan from Peking University Third Hospital, on behalf of Chengdu Guowei Biopharmaceutical Co., Ltd. (hereinafter referred to as “Chengdu Guowei”) / Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as “the Company” or “Salubris”), presented key data from the Phase I clinical study of the innovative siRNA drug SAL0132 (GW906)^[1].

Based on the latest analysis of the single-ascending dose (SAD) study (data cut-off: February 28, 2026), key findings from the Phase I study of SAL0132 (GW906) data presented at ACC.26 include^[1]:

1. Potential for potent and durable AGT suppression: All dose groups achieved >90% reduction in protein levels. Cohort 2 (second lowest dose) achieved a 90% reduction in protein with a single subcutaneous dose and maintained this reduction through Month 9 (follow-up data are still being collected), demonstrating potential for ultra-long-acting therapy.

2. Potential for significant blood pressure lowering: The potential therapeutic dose group (Cohort 3) achieved a mean office blood pressure reduction of approximately 25/13 mmHg at Month 3.

3. Potential for significant diastolic blood pressure (DBP) benefit: Cohort 4 showed a DBP reduction of 15.9 mmHg as early as Week 2, and the antihypertensive effect was sustained, with a reduction of 16.8 mmHg still observed at Month 6.

The above data are based on a randomized, double-blind, placebo-controlled, single-ascending dose Phase I study (final analysis results will be based on the data set generated after database lock).

SAL0132 (GW906) is a GalNAc-conjugated siRNA drug that precisely targets hepatic angiotensinogen (AGT). By blocking the RAAS system at its source, SAL0132 aims to achieve long-acting, stable blood pressure lowering through a durable mechanism of action, thereby improving patient compliance^[1].

In 2025, the Company obtained exclusive license rights from Chengdu Guowei to the intellectual property and technical information related to the API and formulation of the investigational AGT-siRNA drug GW906 for the China market (i.e., mainland China, Taiwan, Hong Kong and Macau special administrative regions, same below), including but not limited to R&D, registration, manufacturing, and commercialization. SAL0132 (GW906) is currently undergoing a Phase II clinical trial in patients with essential hypertension.

·About AGT^[2]

Angiotensinogen (AGT) is a key precursor protein in the renin-angiotensin system and plays a central role in blood pressure regulation and fluid balance. Genetic variants and abnormal expression levels of AGT are closely associated with hypertension and various cardiovascular and metabolic diseases.

·About siRNA drugs^[3]

Small interfering RNA (siRNA) is typically a short double-stranded RNA composed of base pairs. It acts through the RNA interference (RNAi) mechanism to specifically silence the mRNA of pathogenic target genes at the post-transcriptional level, thereby achieving precision treatment of diseases. siRNA drugs can precisely target disease-causing genes, have the advantages of low risk of drug resistance and long-lasting efficacy, and allow reduced dosing frequency, which greatly improves patient compliance. They are expected to transform traditional treatment paradigms and hold great application potential in the field of chronic diseases.

·About the RAAS system^[4]

The renin-angiotensin-aldosterone system (RAAS) is a key regulator of blood volume, electrolyte balance, and systemic vascular resistance. The RAAS system maintains the physiological functions of the heart, blood vessels, and kidneys by regulating vascular tone and fluid balance. In addition to its physiological functions, the RAAS system plays an important role in the pathophysiology of hypertension, other cardiovascular diseases, and kidney diseases. Drugs that block the RAAS system have shown good therapeutic effects in these diseases.

References:

[1] Announcement of Shenzhen Salubris Pharmaceuticals Co., Ltd. on the R&D progress of SAL0132

[2] Nicholas R. Powell, Tyler Shugg et al. “Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension.” Chronic Diseases and Translational Medicine (2023).

[3] Yu Jiaojiao, et al. New progress in research of small interfering RNA drugs in chronic diseases: from preclinical to clinical. Progress in Pharmaceutical Sciences, 2024, 48(8): 579-591.

[4] Sanooja K et al. Ijppr.Human, 2023; Vol. 27 (1): 533-539.

Disclaimer:

This material is intended to provide knowledge in the field of disease, enhance disease awareness, and is not for promotional purposes.

The information contained herein is for reference only. Please follow the advice or guidance of physicians or other healthcare professionals.

|About Salubris

Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998, is an innovationdriven pharmaceutical company integrating R&D, production, and sales, with a foothold in China and a global vision (Stock Code: 002294). With the mission of “providing outstanding pharmaceutical products for human health,” Salubris focuses on the CKM (cardiovascularkidneymetabolic) chronic disease field, primarily cardiovascular diseases. The company has launched several proprietary products, including hypertension treatments Xinlitan, Fulitan®, Fulian®, and Xinchaotuo; the renal anemia treatment EnnaLuo®; and the type 2 diabetes treatment Xinliting®.

Salubris has established five innovative drug R&D centers globally and three medical device R&D bases, forming innovation platforms covering small molecule chemical drugs, biologics, siRNA and gene editing drugs, and medical devices. The company is dedicated to addressing unmet clinical needs and improving people’s quality of life.